Test Your Knowledge: Onco-Nephrology

The overlap of hematology, oncology, and nephrology has led to the creation of a field called Onconephrology. Cancer survivors are living longer and developing chronic kidney disease. Novel chemotherapy agents are nephrotoxic. The field of paraproteinemias is advancing, and MGUS is now been associated with kidney disease. Cancer centers around the world need a dedicated onconephrologists to take care of these patients. A recent AJKD Core Curriculum article by Cohen et al (freely available) addresses the key issues associated with Onco-nephrology. Test your knowledge on this fascinating field with the questions listed below.

Post prepared by Dr. Rimda Wanchoo, Assistant Professor of Medicine, Hofstra NSLIJ School of Medicine and Dr. Kenar D. Jhaveri, AJKD Blog Editor. For a PDF version of the questions & answers, please click here.

1. Hypomagnesemia from urinary magnesium loss is seen with all of the following medications EXCEPT:
Cisplatin
Incorrect.
Omeprazole
Correct! Hypomagnesemia can occur as a result of gastrointestinal (GI) as well as urinary losses. Proton pump inhibitors are responsible for GI loss of magnesium as they inhibit the TRPM 6/TRPM 7 (Transient Receptor Potential Melastatin channels) located on the intestinal epithelial cells. Urinary magnesium levels are appropriately low in patients with hypomagnesemia due to PPI. Cisplatin, carboplatin, and cetuximab are all responsible for urinary magnesium losses.
Carboplatin
Incorrect.
Cetuximab
Incorrect.
2. What are the lab parameters seen with tumor-induced osteomalacia?
High FGF-23, low 1,25 dihydroxyvitamin D3, low serum phosphorus, normal serum calcium
Correct! Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by elevated phosphatonins (FGF-23), renal phosphate wasting, hypophosphatemia, and abnormal vitamin D metabolism. It is usually seen in benign mesenchymal tumors and head and neck cancers. FGF-23 is an important hormone synthesized by osteocytes and osteoblasts. It is still an enigma as to how FGF-23 down-regulates renal phosphate re-absorption, but it likely occurs in the proximal tubule. FGF-23 also inhibits calcitriol synthesis in the kidney, and stimulates the catabolism of active vitamin D sterols. This way, FGF-23 also indirectly decreases intestinal absorption of phosphate. In addition, it also decreases intestinal sodium phosphate transporters, leading to lower 1,25 vitamin D levels. The calcium levels are usually normal.
Low FGF-23, low 1,25 dihydroxyvitamin D3, high serum phosphorus, normal serum calcium
Incorrect.
High FGF-23, high 1,25 dihydroxyvitamin D3, low serum phosphorus, high serum calcium
Incorrect.
Low FGF-23, high 1,25 dihydroxyvitamin D3, low serum phosphorus, low serum calcium
Incorrect.
3. Which one of the following chemotherapeutic agents causes a capillary leak syndrome?
Sunitinib
Incorrect.
Ifosfamide
Incorrect.
Carmustine
Incorrect.
Interleukin-2
Correct! Table 3 in the Core Curriculum article discusses the different types of renal toxicities of chemotherapy agents. IL-2 leads to decreased calcitriol synthesis capillary leak syndrome, and usually occurs in the first 24-48 hours. Carmustine leads more to a chronic kidney disease. Ifosfamide is known to cause Fanconi syndrome, AKI, CKD, and SIADH. Sunitinib is a tyrosine kinase inhibitor that can cause thrombotic microangiopathy (TMA), proteinuric kidney disease, or acute interstitial nephritis.
4. Which pure BRAF inhibitor is now associated with tubular toxicity in clinical practice?
Sunitinib
Incorrect.
Dabrafenib
Incorrect.
Vemurafenib
Correct! Sunitinib and Axitinib are not pure BRAF inhibitors. Of the two BRAF inhibitors, vemurafenib has been now reported to cause biopsy-proven tubulointerstitial damage. Dabrafenib can cause AKI, but data in sparse. Electrolyte disorders have been reported with these agents as well.
Axitinib
Incorrect.

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s